Tamura Daisuke, DeBiasi Roberta L, Okomo-Adhiambo Margaret, Mishin Vasiliy P, Campbell Angela P, Loechelt Brett, Wiedermann Bernhard L, Fry Alicia M, Gubareva Larisa V
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Divisions of Pediatric Infectious Diseases Departments of Pediatrics Microbiology, Immunology and Tropical Medicine, George Washington University School of Medicine, Washington D.C.
J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.
Prolonged treatment of an immunocompromised child with oseltamivir and zanamivir for A(H1N1)pdm09 virus infection led to the emergence of viruses carrying H275Y and/or E119G in the neuraminidase (NA). When phenotypically evaluated by NA inhibition, the dual H275Y-E119G substitution caused highly reduced inhibition by 4 NA inhibitors: oseltamivir, zanamivir, peramivir, and laninamivir.
对一名免疫功能低下的儿童长期使用奥司他韦和扎那米韦治疗甲型H1N1流感病毒（A(H1N1)pdm09）感染，导致在神经氨酸酶（NA）中出现携带H275Y和/或E119G的病毒。通过NA抑制进行表型评估时，H275Y-E119G双重替换导致4种NA抑制剂（奥司他韦、扎那米韦、帕拉米韦和拉尼米韦）的抑制作用大幅降低。
